HbA1c goal attainment in patients with type 2 diabetes mellitus initiated on oral canagliflozin versus injectable glucagon-like peptide

Trial Profile

HbA1c goal attainment in patients with type 2 diabetes mellitus initiated on oral canagliflozin versus injectable glucagon-like peptide

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2017 New trial record
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top